Sagimet Biosciences Q3 net loss narrows as costs drop

Reuters11-13

<a href="https://laohu8.com/S/SGMT">Sagimet Biosciences</a> Q3 net loss narrows as costs drop

Overview

Sagimet reports Q3 net loss of $12.9 mln
R&D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024
Cash and equivalents stand at $125.5 mln as of September 30, 2025

Outlook

Sagimet anticipates Phase 1 trial data readout for denifanstat and resmetirom in 1H 2026
Company plans Phase 2 trial for denifanstat and resmetirom pending regulatory consultation
Sagimet expects Phase 2 acne trial in 2026 following TVB-3567 Phase 1 trial

Result Drivers

CLINICAL TRIALS - Initiated Phase 1 PK trial for denifanstat and resmetirom combination, targeting MASH with F4 fibrosis
ACNE DEVELOPMENT - Ongoing Phase 1 trial of TVB-3567 for acne indication
COSTS DROP - R&R and G&A expenses decline, helping overall results

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$12.91 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sagimet Biosciences Inc is $28.00, about 68.5% above its November 12 closing price of $8.82

Press Release: ID:nGNX3XMnkp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583850560?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583850560","market":"fut","top_or_hot":-1,"title":"Sagimet Biosciences Q3 net loss narrows as costs drop","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences</a> Q3 net loss narrows as costs drop</title></head><body><p><span>Overview</span></p><ul><li><p>Sagimet reports Q3 net loss of $12.9 mln</p></li><li><p>R&amp;D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024</p></li><li><p>Cash and equivalents stand at $125.5 mln as of September 30, 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Sagimet anticipates Phase 1 trial data readout for denifanstat and resmetirom in 1H 2026</p></li><li><p>Company plans Phase 2 trial for denifanstat and resmetirom pending regulatory consultation</p></li><li><p>Sagimet expects Phase 2 acne trial in 2026 following TVB-3567 Phase 1 trial</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL TRIALS - Initiated Phase 1 PK trial for denifanstat and resmetirom combination, targeting MASH with F4 fibrosis</p></li><li><p>ACNE DEVELOPMENT - Ongoing Phase 1 trial of TVB-3567 for acne indication</p></li><li><p>COSTS DROP - R&amp;R and G&amp;A expenses decline, helping overall results</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$12.91 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Sagimet Biosciences Inc is $28.00, about 68.5% above its November 12 closing price of $8.82</p></li></ul><p>Press Release: <span>ID:nGNX3XMnkp</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sagimet Biosciences Q3 net loss narrows as costs drop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSagimet Biosciences Q3 net loss narrows as costs drop\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 20:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences</a> Q3 net loss narrows as costs drop</title></head><body><p><span>Overview</span></p><ul><li><p>Sagimet reports Q3 net loss of $12.9 mln</p></li><li><p>R&amp;D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024</p></li><li><p>Cash and equivalents stand at $125.5 mln as of September 30, 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Sagimet anticipates Phase 1 trial data readout for denifanstat and resmetirom in 1H 2026</p></li><li><p>Company plans Phase 2 trial for denifanstat and resmetirom pending regulatory consultation</p></li><li><p>Sagimet expects Phase 2 acne trial in 2026 following TVB-3567 Phase 1 trial</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL TRIALS - Initiated Phase 1 PK trial for denifanstat and resmetirom combination, targeting MASH with F4 fibrosis</p></li><li><p>ACNE DEVELOPMENT - Ongoing Phase 1 trial of TVB-3567 for acne indication</p></li><li><p>COSTS DROP - R&amp;R and G&amp;A expenses decline, helping overall results</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$12.91 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Sagimet Biosciences Inc is $28.00, about 68.5% above its November 12 closing price of $8.82</p></li></ul><p>Press Release: <span>ID:nGNX3XMnkp</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0HU:1","article_id":"2583850560","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583850560","pubTimestamp":1763037670,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sagimet Biosciences Q3 net loss narrows as costs dropOverviewSagimet reports Q3 net loss of $12.9 mlnR&D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024Cash and equivalents stand ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SGMT":"Sagimet Biosciences Inc."},"translate_title":"随着成本下降，Sagimet Biosciences第三季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGMT":0.9},"content_text":"Sagimet Biosciences Q3 net loss narrows as costs dropOverviewSagimet reports Q3 net loss of $12.9 mlnR&D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024Cash and equivalents stand at $125.5 mln as of September 30, 2025OutlookSagimet anticipates Phase 1 trial data readout for denifanstat and resmetirom in 1H 2026Company plans Phase 2 trial for denifanstat and resmetirom pending regulatory consultationSagimet expects Phase 2 acne trial in 2026 following TVB-3567 Phase 1 trialResult DriversCLINICAL TRIALS - Initiated Phase 1 PK trial for denifanstat and resmetirom combination, targeting MASH with F4 fibrosisACNE DEVELOPMENT - Ongoing Phase 1 trial of TVB-3567 for acne indicationCOSTS DROP - R&R and G&A expenses decline, helping overall resultsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$12.91 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Sagimet Biosciences Inc is $28.00, about 68.5% above its November 12 closing price of $8.82Press Release: ID:nGNX3XMnkpFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583850560","isCrawlerRequest":true}